Human Cell

, Volume 31, Issue 2, pp 167–174 | Cite as

Establishment and characterization of the NCC–SS1–C1 synovial sarcoma cell line

  • Fusako Kito
  • Rieko Oyama
  • Yoko Takai
  • Marimu Sakumoto
  • Kumiko Shiozawa
  • Zhiwei Qiao
  • Takenori Uehara
  • Akihiko Yoshida
  • Akira Kawai
  • Tadashi Kondo
Research Article


Synovial sarcoma is an aggressive mesenchymal malignancy characterized by unique gene fusions. Tissue culture cells are essential tools for further understanding tumorigenesis and anti-cancer drug development; however, only a limited number of well-characterized synovial sarcoma cell lines exist. Thus, the objective of this study was to establish a patient-derived synovial sarcoma cell line. We established a synovial sarcoma cell line from tumor tissue isolated from a 72-year-old female patient. Prepared cells were analyzed for the presence of gene fusions by fluorescence in situ hybridization, RT-PCR, and karyotyping. In addition, the resulting cell line was characterized by viability, short tandem repeat, colony and spheroid formation, and invasion analyses. Differences in gene enrichment between the primary tumor and cell line were examined by mass spectrometric protein expression profiling and KEGG pathway analysis. Our analyses revealed that the primary tumor and NCC–SS1–C1 cell line harbored the SS18SSX1 fusion gene typical of synovial sarcoma and similar proteomics profiles. In vitro analyses also confirmed that the established cell line harbored invasive, colony-forming, and spheroid-forming potentials. Moreover, drug screening with chemotherapeutic agents and tyrosine kinase inhibitors revealed that doxorubicin, a subset of tyrosine kinase inhibitors, and several molecular targeting drugs markedly decreased NCC–SS1–C1 cell viability. Results from the present study support that the NCC–SS1–C1 cell line will be an effective tool for sarcoma research.


Synovial sarcoma Primary culture cells Proteome Drug response 



We thank Drs. M. Endo, Y. Minami, K. Shimizu, T. Mori, M. Sugawara, Y. Araki, S. Toki, and Ms. R. Nakano (Division of Musculoskeletal Oncology, National Cancer Center Hospital) for sampling tumor tissue specimens from surgically resected materials. We would like to thank Editage ( for English language editing and constructive comments on the manuscript.


This work was supported by the National Cancer Center Research and Development Fund [26-A-3, 26-A-9, and 29-A-2].

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

13577_2018_199_MOESM1_ESM.xlsx (111 kb)
Supplementary material 1 (XLSX 111 kb)
13577_2018_199_MOESM2_ESM.docx (107 kb)
Supplementary material 2 (DOCX 107 kb)
13577_2018_199_MOESM3_ESM.xlsx (5.2 mb)
Supplementary material 3 (XLSX 5291 kb)
13577_2018_199_MOESM4_ESM.xlsx (5.4 mb)
Supplementary material 4 (XLSX 5567 kb)
13577_2018_199_MOESM5_ESM.xlsx (111 kb)
Supplementary material 5 (XLSX 111 kb)
13577_2018_199_MOESM6_ESM.xlsx (103 kb)
Supplementary material 6 (XLSX 102 kb)
13577_2018_199_MOESM7_ESM.xls (140 kb)
Supplementary material 7 (XLS 140 kb)
13577_2018_199_MOESM8_ESM.xlsx (104 kb)
Supplementary material 8 (XLSX 103 kb)
13577_2018_199_MOESM9_ESM.tif (152 kb)
Supplementary material 9 (TIFF 151 kb) Supplementary Fig. 1. Presence of the fusion gene unique to synovial sarcoma in the NCC–SS1–C1 cell line was confirmed by RT-PCR
13577_2018_199_MOESM10_ESM.tif (818 kb)
Supplementary material 10 (TIFF 817 kb) Supplementary Fig. 2. Synovial sarcoma marker expression was analyzed in NCC–SS1–C1 cells by immunostaining
13577_2018_199_MOESM11_ESM.tif (339 kb)
Supplementary material 11 (TIFF 338 kb) Supplementary Fig. 3. The effect of anti-cancer drugs on NCC–SS1–C1 cell growth was assessed in screening studies. The IC50 values are summarized in Supplementary Table 8
13577_2018_199_MOESM12_ESM.tif (333 kb)
Supplementary material 12 (TIFF 332 kb) Supplementary Fig. 4. The growth suppressive effects of 24 tyrosine kinase inhibitors
13577_2018_199_MOESM13_ESM.tif (265 kb)
Supplementary material 13 (TIFF 264 kb) Supplementary Fig. 5. The growth suppressive effects of 99 anti-cancer drugs


  1. 1.
    Vlenterie M, Ho VK, Kaal SE, Vlenterie R, Haas R, van der Graaf WT. Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer. 2015;113:1602–6.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    van der Graaf WT, Orbach D, Judson IR, Ferrari A. Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. Lancet Oncol. 2017;18:e166–75.CrossRefPubMedGoogle Scholar
  3. 3.
    dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer. 2001;30:1–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene. 2001;20:5755–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135–40.PubMedGoogle Scholar
  6. 6.
    Ren T, Lu Q, Guo W, Lou Z, Peng X, Jiao G, et al. The clinical implication of SS18-SSX fusion gene in synovial sarcoma. Br J Cancer. 2013;109:2279–85.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hayakawa K, Ikeya M, Fukuta M, Woltjen K, Tamaki S, Takahara N, et al. Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells. Biochem Biophys Res Commun. 2013;432:713–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol. 2008;97:314–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist. 2002;7:348–59.CrossRefPubMedGoogle Scholar
  10. 10.
    Siehl JM, Thiel E, Schmittel A, Hutter G, Deckert PM, Szelenyi H, et al. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer. 2005;104:611–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97:2530–43.CrossRefPubMedGoogle Scholar
  12. 12.
    van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.CrossRefPubMedGoogle Scholar
  13. 13.
    Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014;50:1137–47.CrossRefPubMedGoogle Scholar
  14. 14.
    Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–37.CrossRefPubMedGoogle Scholar
  16. 16.
    Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pfohler C, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res. 2014;20:499–510.CrossRefPubMedGoogle Scholar
  18. 18.
    Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31:2485–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014;32:3299–306.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Doi T, Ma Y, Dontabhaktuni A, Nippgen C, Nippgen J, Ohtsu A. Phase I study of olaratumab in Japanese patients with advanced solid tumors. Cancer Sci. 2014;105:862–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cellosaurus: a cell line knowledge resource [Internet]. Lausanne: Swiss Institute of Bioinformatics.
  22. 22.
    Kondo T, Seike M, Mori Y, Fujii K, Yamada T, Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics. 2003;3:1758–66.CrossRefPubMedGoogle Scholar
  23. 23.
    Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–62.CrossRefPubMedGoogle Scholar
  24. 24.
    Baehrecke EH, Dang N, Babaria K, Shneiderman B. Visualization and analysis of microarray and gene ontology data with treemaps. BMC Bioinformatics. 2004;5:84.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Fusako Kito
    • 1
  • Rieko Oyama
    • 1
  • Yoko Takai
    • 1
  • Marimu Sakumoto
    • 1
  • Kumiko Shiozawa
    • 2
  • Zhiwei Qiao
    • 2
  • Takenori Uehara
    • 3
  • Akihiko Yoshida
    • 4
  • Akira Kawai
    • 3
  • Tadashi Kondo
    • 1
    • 2
  1. 1.Department of Innovative Seeds EvaluationNational Cancer Center Research InstituteTokyoJapan
  2. 2.Division of Rare Cancer ResearchNational Cancer Center Research InstituteTokyoJapan
  3. 3.Division of Musculoskeletal OncologyNational Cancer Center HospitalTokyoJapan
  4. 4.Department of Pathology and Clinical LaboratoriesNational Cancer Center HospitalTokyoJapan

Personalised recommendations